Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Abstract

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status. (Funded by F. Hoffmann-La Roche/Genentech; IMpower150 ClinicalTrials.gov number, NCT02366143 .).

Keywords

AtezolizumabOncologyMedicineInternal medicineCancerImmunotherapyNivolumab

Affiliated Institutions

Related Publications

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Publication Info

Year: 2018
Type: article
Volume: 378
Issue: 24
Pages: 2288-2301
Citations: 3592
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3592

OpenAlex

Cite This

APA Style

                            
                                
                                    Mark A. Socinski, 
                                
                                    Robert M. Jotte, 
                                
                                    Federico Cappuzzo
                                
                                et al.
                            
                            (2018). 
                            Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. 
                            New England Journal of Medicine
                            , 378
                            (24)
                            , 2288-2301.
                            https://doi.org/10.1056/nejmoa1716948
                        

Identifiers

DOI: 10.1056/nejmoa1716948